Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells

[1]  Boris Klebanov,et al.  Influence of Cationic Lipid Composition on Gene Silencing Properties of Lipid Nanoparticle Formulations of siRNA in Antigen-Presenting Cells , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  Daniel G. Anderson,et al.  Therapeutic siRNA silencing in inflammatory monocytes , 2011, Nature Biotechnology.

[3]  J. Kjems,et al.  Intraperitoneal administration of chitosan/DsiRNA nanoparticles targeting TNFα prevents radiation-induced fibrosis. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  N. Svrzikapa,et al.  In vivo quantification of formulated and chemically modified small interfering RNA by heating-in-Triton quantitative reverse transcription polymerase chain reaction (HIT qRT-PCR) , 2010, Silence.

[5]  John Maraganore,et al.  A status report on RNAi therapeutics , 2010, Silence.

[6]  K. G. Rajeev,et al.  Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  M. Pittet,et al.  Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. , 2010, Circulation.

[8]  Priti Kumar,et al.  Targeted delivery of siRNA to macrophages for anti-inflammatory treatment. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  R. Weissleder,et al.  Hybrid PET-optical imaging using targeted probes , 2010, Proceedings of the National Academy of Sciences.

[10]  Markus G. Manz,et al.  Development of Monocytes, Macrophages, and Dendritic Cells , 2010, Science.

[11]  D. Peer,et al.  RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  K. G. Rajeev,et al.  Rational design of cationic lipids for siRNA delivery , 2010, Nature Biotechnology.

[13]  Kathryn A. Whitehead,et al.  Lipid-like materials for low-dose, in vivo gene silencing , 2010, Proceedings of the National Academy of Sciences.

[14]  D. Greiner,et al.  Targeted Delivery of Small Interfering RNA to Human Dendritic Cells To Suppress Dengue Virus Infection and Associated Proinflammatory Cytokine Production , 2009, Journal of Virology.

[15]  Ralph Weissleder,et al.  Hybrid In Vivo FMT-CT Imaging of Protease Activity in Atherosclerosis With Customized Nanosensors , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[16]  R. Weissleder,et al.  Heterogeneous in vivo behavior of monocyte subsets in atherosclerosis. , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[17]  P. Libby,et al.  Identification of Splenic Reservoir Monocytes and Their Deployment to Inflammatory Sites , 2009, Science.

[18]  Michael S. Goldberg,et al.  Drug Delivery–mediated Control of RNA Immunostimulation , 2009, Molecular Therapy.

[19]  M. Czech,et al.  Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation , 2009, Nature.

[20]  A. Judge,et al.  Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. , 2009, The Journal of clinical investigation.

[21]  Daniel G. Anderson,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[22]  J. Kjems,et al.  Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  J. Kjems,et al.  Chitosan/siRNA Nanoparticle-mediated TNF-α Knockdown in Peritoneal Macrophages for Anti-inflammatory Treatment in a Murine Arthritis Model. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  A. Judge,et al.  Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. , 2008, Human gene therapy.

[25]  Robert Langer,et al.  A combinatorial library of lipid-like materials for delivery of RNAi therapeutics , 2008, Nature Biotechnology.

[26]  D. Peer,et al.  Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target , 2008, Science.

[27]  R. Pierce,et al.  Kupffer cell heterogeneity: functional properties of bone marrow derived and sessile hepatic macrophages. , 2007, Blood.

[28]  B. Davidson,et al.  Transvascular delivery of small interfering RNA to the central nervous system , 2007, Nature.

[29]  M. Manoharan,et al.  RNAi therapeutics: a potential new class of pharmaceutical drugs , 2006, Nature chemical biology.

[30]  Matthias John,et al.  RNAi-mediated gene silencing in non-human primates , 2006, Nature.

[31]  M. Shlomchik,et al.  Attenuated liver fibrosis in the absence of B cells. , 2005, The Journal of clinical investigation.

[32]  J. Foley.  Tipping Points in the Tundra , 2005, Science.

[33]  Matthias John,et al.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.

[34]  G. Griffiths,et al.  Phagocytosis: latex leads the way. , 2003, Current opinion in cell biology.

[35]  J. Cyster,et al.  CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity. , 2002, Immunity.

[36]  Jean Gruenberg,et al.  Role of phosphatidylinositol 3-kinase and Rab5 effectors in phagosomal biogenesis and mycobacterial phagosome maturation arrest , 2001, The Journal of cell biology.

[37]  Rainer Constien,et al.  Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line , 2001, Genesis.

[38]  V. Koteliansky,et al.  Regulation of inflammation by collagen-binding integrins α1β1 and α2β1 in models of hypersensitivity and arthritis , 2000 .

[39]  V. Koteliansky,et al.  Regulation of inflammation by collagen-binding integrins alpha1beta1 and alpha2beta1 in models of hypersensitivity and arthritis. , 2000, The Journal of clinical investigation.

[40]  W. Lesslauer,et al.  Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. , 1996, Journal of immunology.

[41]  J. Seyer,et al.  Collagen-induced arthritis in mice: synergistic effect of E. coli lipopolysaccharide bypasses epitope specificity in the induction of arthritis with monoclonal antibodies to type II collagen. , 1995, Autoimmunity.

[42]  A. Kang,et al.  Induction of arthritis with monoclonal antibodies to collagen. , 1992, Journal of immunology.

[43]  M. Thomas,et al.  The leukocyte common antigen family. , 1989, Annual review of immunology.

[44]  K. Rajewsky,et al.  Expansion and functional activity of Ly‐1+ B cells upon transfer of peritoneal cells into allotype‐congenic, newborn mice , 1987, European journal of immunology.